CRIS Stock Summary and Trading Ideas (Curis | NASDAQ:CRIS)

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis trades on the NASDAQ stock market under the symbol CRIS.

As of November 13, 2026, CRIS stock price declined to $0.44 with 633,956 million shares trading.

CRIS has a beta of 2.78, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.01 to the broad based SPY ETF.

CRIS has a market cap of $1.08 million. This is considered a Sub-Micro Cap stock.

Last quarter Curis reported $0 in Revenue and -$1.94 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.13.

In the last 3 years, CRIS traded as high as $17.49 and as low as $.18.

The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VXF.

CRIS has underperformed the market in the last year with a price return of -60.6% while the SPY ETF gained +13.4%. CRIS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -76.2% and -25.8%, respectively, while the SPY returned -2.8% and -0.2%, respectively.

CRIS support price is $.49 and resistance is $.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS shares will trade within this expected range on the day.